Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | CTSE | P14091 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28703609 | 0.94 | GPR119 (0.40) | GPR119DPP4JAK2 | |
| SCHEMBL21114947 | 0.94 | GPR119 (0.40) | GPR119DPP4JAK2 | |
| SCHEMBL21114946 | 0.94 | GPR119 (0.40) | GPR119DPP4JAK2 | |
| SCHEMBL28679492 | 0.89 | KCNH2 (0.37) | GPR119KCNH2 | |
| SCHEMBL16979065 | 0.84 | KRAS (0.41) | GPR119KCNH2JAK2 | |
| SCHEMBL18996823 | 0.83 | BTK (0.40) | — | |
| SCHEMBL26760030 | 0.82 | GPR119 (0.41) | GPR119KCNH2 | |
| SCHEMBL28995746 | 0.82 | GPR119 (0.41) | GPR119KCNH2 | |
| SCHEMBL19001733 | 0.79 | GPR119 (0.47) | GPR119CTSDCTSEBACE1 | |
| SCHEMBL21115007 | 0.79 | GPR119 (0.39) | GPR119KCNH2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137329-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-114075168-A | Pyrazole derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-113999233-A | BTK inhibitor ring derivative, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210009567-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| US-20200055843-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20190092759-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-03-28 | — | — | US | disclosed |
| US-20180222893-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-08-09 | — | — | US | disclosed |
| US-9975882-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| US-9815822-B2 | — | — | 2017-11-14 | — | — | US | disclosed |
| US-20170174663-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222893-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | GPR119 2616/4885CTSD 2125/4885CTSE 1297/4885 |
| US-20200055843-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | GPR119 2616/4885CTSD 2125/4885CTSE 1297/4885 |
| US-20170174663-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | GPR119 2616/4885CTSD 2125/4885CTSE 1297/4885 |
| US-20190092759-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | GPR119 2616/4885CTSD 2125/4885CTSE 1297/4885 |
| US-20210009567-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | GPR119 2616/4885CTSD 2125/4885CTSE 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.